ASCVD risk · what the calculator misses

ASCVD Risk: What Your 10-Year Score Cannot See

An ASCVD risk score estimates your chance of a heart attack or stroke over the next 10 years from a short list of inputs: age, sex, cholesterol, blood pressure and its treatment, diabetes and smoking. It does not count your waist, visceral fat, fasting insulin, inflammation, ankle-brachial index, chronic pain or nerve damage, and any of those can put your real risk well above or below the printed number.

A risk calculator is an average dressed up as a forecast. It tells you what usually happens to a group of people who share your age, cholesterol and blood pressure. It cannot tell you which member of that group you are. The measurements that would tell you are mostly cheap, quick and missing from the form.

What goes into an ASCVD risk score?

For years the standard tool in the US was the Pooled Cohort Equations, the calculator behind the 2019 American College of Cardiology and American Heart Association prevention guideline. In 2024 the American Heart Association’s replacement, PREVENT, was published, built from health records of more than 3.2 million adults and tested on more than 3.3 million more. Its core inputs are smoking, systolic blood pressure, cholesterol, blood-pressure or statin treatment, diabetes and kidney function, with optional add-ons for urine albumin, HbA1c and a neighborhood deprivation index.

PREVENT ranks people reasonably well. In outside testing, when a person who went on to have a cardiovascular event was paired with one who did not, it gave the higher score to the right person about 79% of the time in women and 76% in men. That is good for a population and still sorts roughly one pair in four or five the wrong way. If you are in that fourth or fifth, the score is not describing you.

Why can two people with the same score have very different arteries?

Because the inputs describe the fuel, not the fire or the plumbing. Two 55-year-olds with identical cholesterol and blood pressure get the same number. One has a 34-inch waist, low fasting insulin and supple arteries. The other carries visceral fat, an insulin level twice as high and an inflamed liver. The calculator cannot see the difference. Here is what can.

The ankle-brachial index

Comparing blood pressure at the ankle with the arm detects narrowed leg arteries, and narrowed leg arteries are rarely the only narrowed arteries. Pooling 16 population studies and 48,294 people, the ABI Collaboration found that a low ABI (0.90 or below) roughly doubled 10-year total mortality, cardiovascular mortality and major coronary events within every Framingham risk category. Adding ABI would have moved about 19% of men and 36% of women into a different risk category. More than a third of women reclassified by one painless test. See ankle-brachial index testing.

Arterial stiffness

Stiff arteries age the heart. In a meta-analysis of 17 studies following 15,877 people for an average of 7.7 years, each 1 m/s rise in aortic pulse wave velocity carried a 14% higher risk of cardiovascular events, after adjustment for age, sex and risk factors. To be precise about what Measura measures: those studies used aortic pulse wave velocity. Measura’s arterial stiffness and endothelial function test derives a stiffness index from cuff-based oscillometric readings and the shape of the fingertip pulse wave. It reads the same property of the arteries by a different route, so it is related evidence, not the same number.

Waist, visceral fat and insulin

Waist circumference adds risk information at every BMI level, which is why an international working group asked for it to be measured like a vital sign. Visceral fat measured by CT or MRI is an independent marker of cardiovascular disease and death. Fasting insulin rises years before glucose. None of the three appear in the calculator’s core inputs. Body composition testing estimates trunk fat in minutes; why it matters is in fat mass versus sick fat.

What are risk-enhancing factors?

The 2019 guideline admits the calculator’s blind spots by listing “risk-enhancing factors” to weigh on top of it, among them metabolic syndrome, chronic inflammatory conditions, an hs-CRP of 2.0 mg/L or more and an ABI below 0.9. Their stated purpose is to help decide whether a borderline patient starts a statin.

Use them differently. The statin trials proved benefit in the populations they enrolled, and those trials rarely enrolled people carrying chronic pain, sick fat and several other diagnoses at once. A risk enhancer tells you something in your terrain is driving disease. That is a reason to find and fix the driver. If you already take a statin, keep reviewing it with the physician who prescribed it rather than changing it on your own.

Do chronic pain and neuropathy belong in your heart risk?

The evidence says yes, and no calculator counts them. In the UK Biobank, among 475,171 adults, chronic widespread pain carried a 48% higher adjusted risk of heart attack, stroke, heart failure or cardiovascular death. The share of cardiovascular disease attributable to chronic pain, 8.6%, was comparable with the share attributable to diabetes, 7.3%. In US adults aged 40 and older, loss of sensation in the feet was tied to a 66% higher risk of cardiovascular death in people with diabetes over 13 years.

Diabetes is in the calculator. Chronic pain, with a comparable footprint, is not. If you live with daily pain or numb, burning feet, say so when your risk is being estimated.

What should you bring to the conversation?

  • Your waist measurement and a body composition result, not just weight.
  • An ankle-brachial index and an arterial stiffness reading.
  • Heart rate variability, a read on the nerves that steer heart rhythm and blood pressure.
  • A metabolic panel built in the order the damage happens: LP-IR first, then fasting insulin on its own and as HOMA-IR (Dr. Padda’s clinic treats a fasting insulin above 10 µIU/mL as high risk), GGT (his cutoff is above 20 U/L), oxidized LDL with the omega-3 index and omega-6 to omega-3 ratio, hs-CRP, 25-OH vitamin D, homocysteine, and B12 with methylmalonic acid or holotranscobalamin. Measura’s laboratory panels cover them.
  • An honest account of pain, numbness, sleep and what you eat.

Dr. Padda describes his own wiring as “bad ADD”: fifty thousand projects at once, including a ground-based slingshot meant to launch payloads into orbit, which ran until the physics killed it. He tells that story because it is the right relationship with any model, a calculator included. Run it, respect it, and drop it the moment the measurement in front of you disagrees.

The so-what: a 10-year score is where the conversation starts. Your measurements are what make it about you, and unlike age, most of them can move.

If you have chest pain, pressure, sudden shortness of breath or new weakness on one side, call 911. Measura testing is for planning, not emergencies.

Frequently asked questions

My ASCVD risk is under 5%. Am I in the clear?

Not necessarily. A low score means people with your inputs usually do well. A low ankle-brachial index, a stiff artery or high fasting insulin can sit underneath a low score, and in the ABI pooled analysis a low ABI roughly doubled risk within every risk category.

Does the ASCVD calculator count obesity?

Not directly. Neither the Pooled Cohort Equations nor PREVENT includes waist size, visceral fat or body composition among its core inputs. Obesity enters only through what it has already done to blood pressure, cholesterol, blood sugar and the kidneys.

Which number moves fastest when I change my habits?

Usually fasting insulin and waist circumference, which tend to move first. hs-CRP tends to follow as fat shrinks. Arterial stiffness changes more slowly, which is why it is worth re-measuring on a longer schedule.

Add the numbers your score leaves out

Bring your calculated risk. Leave with your waist, body composition, ankle-brachial index, arterial stiffness and metabolic markers beside it.

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

  • Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., et al. (2019). 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 140(11), e596-e646. https://doi.org/10.1161/CIR.0000000000000678 (PMID 30879355)
  • Khan, S. S., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Surapaneni, A., et al. (2024). Development and Validation of the American Heart Association’s PREVENT Equations. Circulation, 149(6), 430-449. https://doi.org/10.1161/CIRCULATIONAHA.123.067626 (PMID 37947085)
  • Collaboration, A. B. I., Fowkes, F. G. R., Murray, G. D., Butcher, I., Heald, C. L., Lee, R. J., et al. (2008). Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA, 300(2), 197-208. https://doi.org/10.1001/jama.300.2.197 (PMID 18612117)
  • Vlachopoulos, C., Aznaouridis, K., & Stefanadis, C. (2010). Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. Journal of the American College of Cardiology, 55(13), 1318-1327. https://doi.org/10.1016/j.jacc.2009.10.061 (PMID 20338492)
  • Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., et al. (2020). Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology, 16(3), 177-189. https://doi.org/10.1038/s41574-019-0310-7 (PMID 32020062)
  • Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., et al. (2019). Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. The Lancet Diabetes & Endocrinology, 7(9), 715-725. https://doi.org/10.1016/S2213-8587(19)30084-1 (PMID 31301983)
  • Rönnegård, A.-S., Nowak, C., Äng, B., & Ärnlöv, J. (2022). The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank. European Journal of Preventive Cardiology, 29(15), 1994-2002. https://doi.org/10.1093/eurjpc/zwac127 (PMID 35727954)
  • Hicks, C. W., Wang, D., Matsushita, K., Windham, B. G., & Selvin, E. (2021). Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults : A Prospective Cohort Study. Annals of Internal Medicine, 174(2), 167-174. https://doi.org/10.7326/M20-1340 (PMID 33284680)

Related reading

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed .

Filed under: